Zhongshan University Launches Investigation into Suspected Data Fabrication in Affiliated Hospital Research Papers

The University’s Swift Response to Allegations

On May 5, 2026, Sun Yat-sen University, also known as Zhongshan University, issued a formal statement through its Academic Integrity Office announcing the launch of an official investigation into allegations of data fabrication and image irregularities in research papers authored by a doctor at its affiliated hospital. The statement emphasized the institution’s zero-tolerance policy toward academic misconduct, pledging a thorough review and appropriate disciplinary actions based on findings. This development has captured significant attention within China’s higher education and medical research communities, highlighting ongoing challenges in maintaining research standards at top-tier institutions.

Sun Yat-sen University, one of China’s leading comprehensive universities located in Guangzhou, Guangdong Province, boasts a prestigious medical school and affiliated hospitals renowned for oncology research. The implicated facility is the Sun Yat-sen University Cancer Center, a key player in national cancer prevention and treatment efforts. The rapid response underscores the university’s commitment to upholding scholarly standards amid growing public scrutiny facilitated by social media platforms.

Profile of the Accused Researcher

The individual at the center of the controversy is Kang Tiebang, a highly accomplished professor and researcher at the Sun Yat-sen University Cancer Center. Holding prestigious titles such as National Outstanding Youth Fund recipient, Changjiang Scholar Distinguished Professor, and Guangdong Province Pearl River Talent Plan awardee, Kang has been deputy director of the National Key Laboratory for South China Regional Prevention and Treatment of Malignant Tumors. His career trajectory includes a PhD from Bielefeld University in Germany in 2003, postdoctoral work at MD Anderson Cancer Center and Washington University in St. Louis, and a full-time return to China in 2008 via SYSU’s Hundred Talents Program.

Kang’s research focuses on tumor-targeted therapy, immunotherapy, novel tumor targets, cell vesicles, drug resistance, and metastasis. As corresponding author, he has published over 70 papers in top journals including Science, Nature Cell Biology, Nature Cancer, and Cell Research. Notable achievements include leading National Key R&D projects, “973” Plan subprojects, and winning first prize in the Chinese Anti-Cancer Association Science and Technology Award in 2025. He has mentored 40 PhD graduates and postdocs, many securing their own national grants.

Detailed Allegations Against the Research

The accusations surfaced through a detailed video by popular Bilibili whistleblower “Geng Tongxue Jiang Gushi” (Geng Classmate Tells Stories), known for exposing academic irregularities. The primary target is Kang’s 2020 paper in Nature Cell Biology titled “Chromosomal Translocation-derived Aberrant RAB22A Drives Osteosarcoma Metastasis.” Specific issues raised include:

• Image duplication: Figures showing similar patterns across different experiments, previously noted on PubPeer in 2021, leading to a correction in February 2024 for “figure production errors” that did not affect conclusions.
• Suspicious mouse images: Alleged use of the same photo with altered fluorescence intensities to represent distinct results.
• Data anomalies: Identical data points or values that match only after rounding, suggesting manipulation.

Additional papers are implicated, though details vary. These claims have sparked widespread online discussion, with netizens questioning how high-profile publications evaded initial scrutiny.

The Whistleblower and Social Media’s Role

“Geng Tongxue Jiang Gushi,” with millions of followers on Bilibili, specializes in dissecting scientific papers for fraud. The real-name report on Kang’s work rapidly went viral, prompting the university’s action. This incident exemplifies how digital platforms empower citizen science watchdogs, accelerating accountability in opaque academic environments. Similar exposures have led to investigations at other Chinese institutions, pressuring universities to respond publicly.

Sun Yat-sen University’s Reputation at Stake

Ranked among China’s top universities, SYSU excels in medicine and life sciences, with its Cancer Center contributing significantly to national health initiatives. Past incidents, such as lab safety concerns or isolated misconduct cases, have not tarnished its standing, but this probe tests its research governance. The affiliated hospital handles thousands of patients annually, blending clinical care with cutting-edge research, making integrity paramount for public trust.

Research Misconduct Trends in Chinese Higher Education

China’s academic landscape has seen intensified scrutiny. In 2026, the National Natural Science Foundation of China (NSFC) issued its first batch of misconduct notices, sanctioning 46 scholars across 20 cases for issues like proxy writing, plagiarism, and data buying. Local hospitals and universities dominate retraction lists, with over 60% of global biomedical retractions from China between 2014-2024 per Nature analysis. Factors include “paper mills,” publication pressures for promotions, and inadequate oversight.

Universities like SYSU have established Academic Integrity Offices, aligning with national policies promoting “zero tolerance.” Yet, challenges persist: rapid research expansion, incentive structures favoring quantity, and AI tools enabling sophisticated fraud. NSFC’s 2026通报 details penalties like project cancellations and funding recovery.

Past Incidents at SYSU and Affiliated Institutions

SYSU has faced prior scrutiny, including retractions from its affiliates and lab controversies. In 2023, Zhongshan Hospital’s Shu Hua Breast Cancer Center drew attention after three young doctors were diagnosed with cancer, sparking speculation on lab hazards—though officially attributed to coincidence. These events highlight vulnerabilities in high-pressure research environments where clinical duties intersect with basic science.

National Policies and Institutional Safeguards

China’s Ministry of Education and NSFC enforce strict guidelines, mandating self-checks and blacklists. SYSU’s policy mirrors this, covering fabrication, falsification, and plagiarism with investigations leading to warnings, demotions, or firings. International collaborations add pressure, as journals like Nature demand corrections or retractions. Training in research ethics is now standard for graduate students.

Recent reforms include AI detection tools and third-party audits, aiming to curb “paper factories.” For medical research, clinical trial registries and data repositories enhance transparency. 2026专项整治 mandates universities to audit publications.

Potential Ramifications for Stakeholders

If substantiated, consequences could include paper retractions, grant revocations, title stripping, and career halt for Kang and co-authors. Students and postdocs under his mentorship may face indirect impacts on publications and funding. The Cancer Center risks funding cuts and collaborations. Patients relying on derived therapies underscore ethical stakes in oncology research.

• Personal: Loss of prestige, legal repercussions under China’s updated integrity laws.
• Institutional: Mandatory reporting to NSFC, potential leadership changes.
• Systemic: Renewed calls for incentive reform, emphasizing quality over quantity.

Implications for Cancer Research in China

Kang’s work on metastasis mechanisms like RAB22A fusions informs osteosarcoma treatments, a pediatric cancer. Fraud undermines progress, eroding trust in clinical translations. China’s cancer burden—700,000 annual osteosarcoma-related deaths—demands robust science. This case may prompt peer reviews of similar high-impact studies.

Pathways to Stronger Research Integrity

Universities are adopting proactive measures: mandatory data management plans, open-access repositories, and whistleblower protections. Training workshops, AI plagiarism detectors, and international benchmarks like COPE guidelines are proliferating. Collaborative oversight between institutions, journals, and funders could prevent escalations. For aspiring researchers, prioritizing ethics yields sustainable careers—explore opportunities via academic CV tips.

Future Outlook and Lessons Learned

As the investigation unfolds, SYSU’s handling will set precedents. China’s higher education, producing 10 million graduates yearly, must balance innovation with integrity amid global competition. This scandal, while regrettable, catalyzes reforms, fostering a culture where transparency trumps accolades. Stakeholders await transparent updates, reinforcing that science thrives on trust.

Photo by Fidel Fernando on Unsplash